Eledon Pharmaceuticals
ELDN
36 hedge funds and large institutions have $34.7M invested in Eledon Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 35 → 36 (+1)
3.84% less ownership
Funds ownership: 58.94% → 55.1% (-3.8%)
33% less capital invested
Capital invested by funds: $52.1M → $34.7M (-$17.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.12M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$353K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$202K |
| 4 |
Millennium Management
New York
|
+$130K |
| 5 |
BlackRock
New York
|
+$79.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.53M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.53M |
| 3 |
Morgan Stanley
New York
|
-$509K |
| 4 |
Renaissance Technologies
New York
|
-$131K |
| 5 |
VF
Virtu Financial
New York
|
-$115K |
ELDN Hedge Fund Activity: Q4 2021 in Review
36 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2021, worth a combined $34.7M — down 33% from $52.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ELDN positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $1.12M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $2.53M sold.
- 36 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2021, up from 35 in Q3 2021.
- Funds reported $34.7M of Eledon Pharmaceuticals stock for Q4 2021, down 33% quarter-over-quarter.
- 5 funds opened new Eledon Pharmaceuticals positions in Q4 2021 and 4 closed out, a net change of +1 holder.
- The largest Eledon Pharmaceuticals buyer in Q4 2021 was Point72 Asset Management, an estimated $1.12M added.
- The largest Eledon Pharmaceuticals seller in Q4 2021 was Adage Capital Partners, an estimated $2.53M sold.
Based on aggregated 13F filings for Q4 2021.